We treated 10 patients who had chronic non-A,non-B hepatitis with recombinant human alpha interferon in varying doses (0.5 to 5 million units) daily, every other day, or three times weekly for up to 12 months. In 8 of the 10 patients, elevated serum aminotransferase levels decreased rapidly during therapy and eventually fell into the normal or nearly normal range. In two of these patients, the interferon therapy was stopped after four months, and in both cases, a prompt return of aminotransferase activities to pretreatment values occurred. Prolonged treatment was associated with a sustained improvement in aminotransferase levels; in three cases, biopsy specimens obtained after one year of therapy showed marked improvement in hepatic histology, even though low doses of alpha interferon had been used. These preliminary findings, although not adequately controlled, suggest that long-term, low-dose alpha interferon therapy may be effective in controlling the disease activity in some patients with chronic non-A,non-B hepatitis. A prospective controlled trial is now needed to assess the role of interferon therapy in this disease.
This article has been cited by other articles:
Torres-Puente, M., Cuevas, J. M., Jimenez-Hernandez, N., Bracho, M. A., Garcia-Robles, I., Carnicer, F., del Olmo, J., Ortega, E., Moya, A., Gonzalez-Candelas, F.
(2007). Contribution of insertions and deletions to the variability of hepatitis C virus populations. J. Gen. Virol.
88: 2198-2203
[Abstract][Full Text]
Manns, M P, Wedemeyer, H, Cornberg, M
(2006). Treating viral hepatitis C: efficacy, side effects, and complications.. Gut
55: 1350-1359
[Full Text]
Matthews, J. D., Bini, E. J.
(2004). Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C. Journal of Pharmacy Practice
17: 229-238
[Abstract]
Yoshida, H, Tateishi, R, Arakawa, Y, Sata, M, Fujiyama, S, Nishiguchi, S, Ishibashi, H, Yamada, G, Yokosuka, O, Shiratori, Y, Omata, M
(2004). Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut
53: 425-430
[Abstract][Full Text]
Kakizoe, T.
(2003). Chemoprevention of Cancer - Focusing on Clinical Trials. Jpn J Clin Oncol
33: 421-442
[Abstract][Full Text]
Herrine, S. K.
(2002). Approach to the Patient with Chronic Hepatitis C Virus Infection. ANN INTERN MED
136: 747-757
[Abstract][Full Text]
Walsh, K, Alexander, G J M
(2001). Update on chronic viral hepatitis. Postgrad. Med. J.
77: 498-505
[Abstract][Full Text]
Lauer, G. M., Walker, B. D.
(2001). Hepatitis C Virus Infection. NEJM
345: 41-52
[Full Text]
Frese, M., Pietschmann, T., Moradpour, D., Haller, O., Bartenschlager, R.
(2001). Interferon-{{alpha}} inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol.
82: 723-733
[Abstract][Full Text]
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S., Yamada, G., Omata, M., for the IHIT Study Group,
(1999). Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan. ANN INTERN MED
131: 174-181
[Abstract][Full Text]
Cresta, P, Musset, L, Cacoub, P, Frangeul, L, Vitour, D, Poynard, T, Opolon, P, Nguyen, D-T, Golliot, F, Piette, J-C, Huraux, J-M, Lunel, F
(1999). Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut
45: 122-128
[Abstract][Full Text]
Shiota, G., Harada, K.-i., Ishida, M., Tomie, Y., Okubo, M., Katayama, S., Ito, H., Kawasaki, H.
(1999). Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis
20: 59-63
[Abstract][Full Text]
Ohno, Y., Fujimoto, M., Nishimura, A., Aoki, N.
(1998). Change of Peripheral Levels of Pituitary Hormones and Cytokines after Injection of Interferon (IFN)-{beta} in Patients with Chronic Hepatitis C. J. Clin. Endocrinol. Metab.
83: 3681-3687
[Abstract][Full Text]
Polyak, S. J., McArdle, S., Liu, S.-L., Sullivan, D. G., Chung, M., Hofgartner, W. T., Carithers, R. L. Jr., McMahon, B. J., Mullins, J. I., Corey, L., Gretch, D. R.
(1998). Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection. J. Virol.
72: 4288-4296
[Abstract][Full Text]
Hoofnagle, J. H., Di Bisceglie, A. M.
(1997). The Treatment of Chronic Viral Hepatitis. NEJM
336: 347-356
[Full Text]
Bennett, M. A., Allen, R. D.
(1990). High-Technology Home Pharmacotherapy, II: An Overview of the Newest Home Therapies. Journal of Pharmacy Practice
3: 40-47
[Abstract]
Previous
